XBiotech Historical Cash Flow

XBIT Stock  USD 3.82  0.02  0.53%   
Analysis of XBiotech cash flow over time is an excellent tool to project XBiotech future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Cash of 40.4 M or Stock Based Compensation of 4.8 M as it is a great indicator of XBiotech ability to facilitate future growth, repay debt on time or pay out dividends.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining XBiotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether XBiotech is a good buy for the upcoming year.
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XBiotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy XBiotech Stock please use our How to Invest in XBiotech guide.

About XBiotech Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in XBiotech balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which XBiotech's non-liquid assets can be easily converted into cash.

XBiotech Cash Flow Chart

At this time, XBiotech's Investments are comparatively stable compared to the past year.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by XBiotech to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of XBiotech operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.
Most accounts from XBiotech's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into XBiotech current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XBiotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy XBiotech Stock please use our How to Invest in XBiotech guide.At this time, XBiotech's Investments are comparatively stable compared to the past year.

XBiotech cash flow statement Correlations

-0.50.270.22-0.620.06-0.83-0.20.820.620.6-0.040.67-0.560.870.010.97-0.810.83-0.03
-0.5-0.39-0.450.820.170.080.31-0.080.2-0.81-0.04-0.420.62-0.150.22-0.520.07-0.090.03
0.27-0.390.85-0.250.29-0.01-0.390.040.070.420.040.79-0.250.070.070.280.080.010.72
0.22-0.450.85-0.380.120.170.0-0.18-0.110.59-0.040.78-0.41-0.110.040.210.26-0.170.74
-0.620.82-0.25-0.380.50.150.1-0.150.24-0.94-0.07-0.40.64-0.260.24-0.660.16-0.140.27
0.060.170.290.120.5-0.29-0.350.290.58-0.4-0.140.27-0.040.210.38-0.01-0.240.30.57
-0.830.08-0.010.170.15-0.290.15-1.0-0.86-0.08-0.09-0.460.31-0.99-0.09-0.830.99-0.980.14
-0.20.31-0.390.00.1-0.350.15-0.19-0.14-0.090.19-0.06-0.08-0.150.08-0.160.14-0.18-0.09
0.82-0.080.04-0.18-0.150.29-1.0-0.190.860.070.10.46-0.290.980.10.82-0.990.98-0.14
0.620.20.07-0.110.240.58-0.86-0.140.86-0.2-0.10.43-0.050.820.240.54-0.830.890.23
0.6-0.810.420.59-0.94-0.4-0.08-0.090.07-0.2-0.010.52-0.570.19-0.210.61-0.070.070.01
-0.04-0.040.04-0.04-0.07-0.14-0.090.190.1-0.1-0.010.08-0.10.08-0.170.12-0.09-0.04-0.25
0.67-0.420.790.78-0.40.27-0.46-0.060.460.430.520.08-0.560.50.080.68-0.380.450.58
-0.560.62-0.25-0.410.64-0.040.31-0.08-0.29-0.05-0.57-0.1-0.56-0.30.19-0.60.29-0.30.03
0.87-0.150.07-0.11-0.260.21-0.99-0.150.980.820.190.080.5-0.30.160.88-0.980.97-0.15
0.010.220.070.040.240.38-0.090.080.10.24-0.21-0.170.080.190.16-0.05-0.080.120.23
0.97-0.520.280.21-0.66-0.01-0.83-0.160.820.540.610.120.68-0.60.88-0.05-0.810.8-0.12
-0.810.070.080.260.16-0.240.990.14-0.99-0.83-0.07-0.09-0.380.29-0.98-0.08-0.81-0.980.24
0.83-0.090.01-0.17-0.140.3-0.98-0.180.980.890.07-0.040.45-0.30.970.120.8-0.98-0.1
-0.030.030.720.740.270.570.14-0.09-0.140.230.01-0.250.580.03-0.150.23-0.120.24-0.1
Click cells to compare fundamentals

XBiotech Account Relationship Matchups

XBiotech cash flow statement Accounts

202020212022202320242025 (projected)
Change In Cash(477.2M)(383K)(79.7M)42.7M38.4M40.4M
Stock Based Compensation12.6M4.5M5.1M3.3M3.8M4.8M
Free Cash Flow(68.9M)65.9M(15.4M)(19.1M)(22.0M)(23.0M)
Change In Working Capital(68.7M)79.7M7.6M2.7M3.1M3.3M
Begin Period Cash Flow714.6M237.4M237.0M157.3M180.9M146.4M
Other Cashflows From Financing Activities10.3M428.0M(63.9M)(14K)(16.1K)(15.3K)
Depreciation2.2M2.6M2.6M1.7M2.0M1.8M
Capital Expenditures3.7M3.5M585K362K325.8K309.5K
Total Cash From Operating Activities(65.1M)69.4M(14.8M)(18.7M)(21.5M)(22.6M)
Net Income(11.2M)(17.4M)(32.9M)(24.6M)(28.2M)(26.8M)
Total Cash From Financing Activities(409.7M)(67.0M)33K(9K)(8.1K)(8.5K)
End Period Cash Flow237.4M237.0M157.3M200.0M230.0M163.9M
Sale Purchase Of Stock201K41.8M(420M)8.0M7.2M7.6M
Total Cashflows From Investing Activities674.8M(3.7M)(3.5M)(63.9M)(73.5M)(69.8M)
Change To Operating Activities51.8M(53.2M)76.9M(653K)(751.0K)(713.4K)
Change To Netincome2.9M12.5M4.5M7.9M9.0M5.9M
Change To Liabilities53.8M(4.8M)(279K)741K852.2K809.5K
Cash And Cash Equivalents Changes698.8M(478.6M)(1.1M)(78.7M)(70.8M)(67.3M)
Cash Flows Other Operating(746.0M)(12.2M)75.9M8.1M7.3M7.6M
Investments(3.7M)(3.5M)(63.3M)57.7M51.9M64.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for XBiotech Stock Analysis

When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.